Systemic Sclerosis clinical trials

Explore recruiting systemic sclerosis clinical trials.

Recruiting systemic sclerosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Systemic Sclerosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADD-ON TRIAL EVALUATING EFFICACY AND SAFETY OF HYDROXYCHLOROQUINE IN EARLY SYSTEMIC SCLEROSIS (SSc)- HYDROXYSSc

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Comparison of treatment efficacy in the patients with Systemic sclerOsis: dapagliFlozin vs. Tocilizumab – a randomized head to head study

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, multi-part, five-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis

Italy, Spain, France, Netherlands, Germany, Austria +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Netherlands, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab in participants with diffuse cutaneous systemic sclerosis

France, Greece, Portugal, Hungary, Italy, Germany +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase I/II randomized clinical trial of allogeneic adipose tissue-derived mesenchymal stromal cells systemic infusion in severe systemic sclerosis MSC-AT-SSc

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Systemic Sclerosis trials by city

Systemic Sclerosis in Toronto Systemic Sclerosis in Vancouver Systemic Sclerosis in Montreal Systemic Sclerosis in Calgary Systemic Sclerosis in Edmonton Systemic Sclerosis in Ottawa Systemic Sclerosis in Winnipeg Systemic Sclerosis in Quebec City Systemic Sclerosis in Hamilton Systemic Sclerosis in Kitchener Systemic Sclerosis in London Systemic Sclerosis in Halifax Systemic Sclerosis in New York Systemic Sclerosis in Los Angeles Systemic Sclerosis in Chicago Systemic Sclerosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease